<DOC>
	<DOCNO>NCT00085527</DOCNO>
	<brief_summary>RATIONALE : FR901228 may stop growth tumor cell block enzymes necessary growth . PURPOSE : This phase II trial study well FR901228 work treat patient relapsed refractory advance ovarian epithelial cancer .</brief_summary>
	<brief_title>FR901228 Treating Patients With Relapsed Refractory Advanced Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate ( complete partial ) patient relapse refractory advanced ovarian epithelial carcinoma treat FR901228 ( depsipeptide ) . - Determine toxicity drug patient . Secondary - Correlate clinical response platinum sensitivity patient treat drug . - Correlate clinical response P-glycoprotein expression p53 status patient treat drug . OUTLINE : This multicenter study . Patients stratify accord response prior platinum administration ( platinum resistant v platinum sensitive ) . Patients receive FR901228 ( depsipeptide ) IV 4 hour day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 20-37 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm ovarian epithelial carcinoma Advanced disease Relapsed OR refractory 1 , 1 , prior platinum taxanebased regimen Refractory disease define disease progression platinum taxanebased therapy Relapsed disease define platinum taxane resistant sensitive Platinum taxane resistance define relapse within 6 month prior platinum taxane therapy Platinum taxane sensitivity define relapse &gt; 6 month last platinum taxane treatment Measurable evaluable disease Measurable disease define least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan Evaluable disease determine elevation CA 125 ( ≥ 2 time upper limit normal [ ULN ] ) , ascites , pleural effusion No known brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status SWOG 02 OR Karnofsky 60100 % Life expectancy At least 24 week Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 WBC ≥ 3,000/mm^3 Hepatic AST ALT ≤ 2.5 time ULN Bilirubin normal Renal Creatinine normal OR Creatinine clearance ≥ 60 mL/min Cardiovascular QTc &lt; 500 msec LVEF &gt; 40 % MUGA No significant cardiac disease No symptomatic congestive heart failure No unstable poorly control angina pectoris No uncontrolled dysrhythmias No New York Heart Association class III IV congestive heart failure No myocardial infarction within past year No prior serious ventricular arrhythmia ( ventricular tachycardia ventricular fibrillation ≥ 3 beat row ) No left ventricular hypertrophy EKG Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Potassium ≥ 4.0 mmol/L Magnesium ≥ 2.0 mg/dL No prior allergic reaction attribute compound similar chemical biological composition FR901228 ( depsipeptide ) No concurrent uncontrolled illness No active ongoing infection No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent biologic agent Chemotherapy See Disease Characteristics More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No prior FR901228 ( depsipeptide ) No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery Prior surgical resection allow Other No concurrent drug know HDI activity ( e.g. , sodium valproate ) No concurrent agent cause QTc prolongation No concurrent combination antiretroviral therapy HIVpositive patient No concurrent hydrochlorothiazide No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
</DOC>